Fertility preservation in women with benign gynaecological conditions.
Pietro SantulliChristophe BlockeelMathilde BourdonGiovanni CoticchioAlison CampbellMichel De VosKirsten Tryde MacklonAnja PinborgJuan A Garcia-VelascoPublished in: Human reproduction open (2023)
Although a wealth of data has been published regarding fertility preservation (FP) in women with malignant diseases who receive gonadotoxic treatment, the role of FP in non-malignant conditions has been studied to a much lesser extent. These include benign haematological, autoimmune, and genetic disorders, as well as a multitude of benign gynaecological conditions (BGCs) that may compromise ovarian reserve and/or reproductive potential due to pathogenic mechanisms or as a result of medical or surgical treatments. Alongside accumulating data that document the reproductive potential of cryopreserved oocytes and ovarian tissue, there is potential interest in FP for women with BGCs at risk of infertility; however, there are currently insufficient data about FP in women with BGCs to develop guidelines for clinical practice. The purpose of this article is to appraise the available evidence regarding FP for BGC and discuss potential strategies for FP based on estimated ovarian impairment and on short-term and long-term reproductive goals of patients. Cost-effectiveness considerations and patients' perspectives will also be discussed.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- clinical practice
- electronic health record
- healthcare
- public health
- prognostic factors
- randomized controlled trial
- human health
- adipose tissue
- skeletal muscle
- climate change
- risk assessment
- machine learning
- patient reported outcomes
- insulin resistance
- polycystic ovary syndrome
- bone marrow
- deep learning